[1]古力尼尕尔·麦麦提吐尔孙 付真彦.肺癌靶向治疗药物EGFR-TKI与其心脏毒性的研究进展[J].心血管病学进展,2022,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
　GULINIGAER·Maimaitituersun,FU Zhenyan.EGFR-TKI and Its Cardiotoxicity in Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
点击复制

肺癌靶向治疗药物EGFR-TKI与其心脏毒性的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年2期
页码:
128
栏目:
综述
出版日期:
2022-02-25

文章信息/Info

Title:
EGFR-TKI and Its Cardiotoxicity in Lung Cancer
作者:
古力尼尕尔·麦麦提吐尔孙1 付真彦2
(1.新疆医科大学研究生院,新疆 乌鲁木齐 830054; 2.新疆医科大学第一附属医院,新疆 乌鲁木齐 830054)
Author(s):
GULINIGAER·Maimaitituersun1;  FU Zhenyan2
Xinjiang Medical University Graduate School,Urumqi 830054,Xinjiang,China; 2.The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang,China)
关键词:
非小细胞肺癌; 靶向药物; 心脏毒性; 表皮生长因子受体抑制剂
Keywords:
Non-small cell lung cancer; Targeted drug; Cardiotoxicity; Epidermal growth factor receptor inhibitors
DOI:
10.16806/j.cnki.issn.1004-3934.2022.02.009
摘要:
靶向药物治疗的问世极大地改变了晚期非小细胞肺癌的治疗格局，但靶向药物抗癌治疗的心脏毒性副作用严重影响非小细胞肺癌的预后，甚至成为了癌症患者第二大死亡原因。因此，早期识别靶向药物心脏毒性副作用，对心血管疾病的预防及治疗至关重要。现探讨新型靶向药物表皮生长因子受体抑制剂可能引起的心脏毒性副作用，包括血栓栓塞事件、心力衰竭、心肌病、心律失常及高血压等，并总结其各自的心血管不良反应机制，对晚期肺癌患者的心脏管理提供有益的建议，最大限度地提高肺癌幸存者的治疗效果。
Abstract:
The advent of targeted drug therapy has greatly changed the treatment pattern of advanced non-small cell lung cancer(NSCLC) and become a good news for lung cancer patients. However,the cardiotoxic side effects of targeted drug therapy seriously affect the prognosis of NSCLC and even become the second leading cause of death in cancer patients.?Therefore,early identification of cardiotoxicity of targeted drugs is crucial for the prevention and treatment of cardiovascular diseases.?This review aims to explore the potential cardiotoxic side effects caused by novel targeted drugs— epidermal growth factor receptor inhibitors,including thromboembolic events,heart failure,cardiomyopathy,arrhythmia,hypertension,etc. In addition,the mechanisms of cardiovascular adverse reactions are summarized to provide useful suggestions for cardiac management of patients with advanced lung cancer and maximize the therapeutic effect of lung cancer survivors

参考文献/References:

[1] Bade BC,Dela Cruz CS. Lung cancer 2020:epidemiology,etiology,and prevention[J]. Clin Chest Med,2020,41(1):1-24.

[2] Nasim F,Sabath BF,Eapen GA. Lung cancer[J]. Med Clin North Am,2019,103(3):463-473.

[3] Wang Y,Zou S,Zhao Z,et al. New insights into small-cell lung cancer development and therapy[J]. Cell Biol Int,2020,44(8):1564-1576.

[4]蒋中秀,崔国元,张晓晔. 安罗替尼治疗晚期非小细胞肺癌的疗效与安全性的Meta分析[J]. 现代肿瘤医学,2021,29(2):242-248.

[5] Sun X,Xu S,Yang Z,et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer:a patent review (2014-present)[J]. Expert Opin Ther Pat,2021,31(3):223-238.

[6] Zhang J,Yang PL,Gray NS. Targeting cancer with small molecule kinase inhibitors[J]. Nat Rev Cancer,2009,9(1):28-39.

[7] Sankar K,Gadgeel SM,Qin A. Molecular therapeutic targets in non-small celllung cancer[J]. Expert Rev Anticanc,2020,20(8):647-661.

[8]Abdelgalil AA,Al-Kahtani HM,Al-Jenoobi FI. Erlotinib[J]. Profiles Drug Subst Excip Relat Methodol,2020,45:93-117.

[9]Ayati A,Moghimi S,Salarinejad S,et al. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy[J]. Bioorg Chem,2020,99:103811.

[10] Galvano A,Guarini A,Iacono F,et al. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy[J]. Expert Opin Drug Saf,2019,18(6):485-496.

[11] Lynch DJ,Kickler TS,Rade JJ. Recurrent myocardial infarction associated with gefitinib therapy[J]. J Thromb Thrombolysis,2011,32(1):120-124.

[12] Zaborowska-Szmit M,Krzakowski M,Kowalski DM,et al. Cardiovascular complications of systemic therapy in non-small-cell lung cancer[J]. J Clin Med,2020,9(5):1268.

[13] Shota O,Takuya O, Tateaki N, et al. Gefitinib-induced cardiomyopathy in epidermal growth receptor-mutated ncslc[J]. J Thorac Oncol,2018,13(10):e207-e208.

[14] Han D,Tan H,Sun C,et al. Amiodarone-induced life-threatening torsade de pointes in an end-stage lung cancer patient receiving gefitinib[J]. Oxf Med Case Reports,2019,2019(1):omy122.

[15] Shah RR,Morganroth J,Shah DR. Cardiovascular safety of tyrosine kinase inhibitors:with a special focus on cardiac repolarisation (QT interval)[J]. Drug safety,2013,36(5):295-316.

[16] Alhoshani A,Alanazi FE,Alotaibi MR,et al. EGFR inhibitor gefitinib induces cardiotoxicity through the modulation of cardiac PTEN/Akt/FoxO3a pathway and reactive metabolites formation:in vivo and in vitro rat studies[J]. Chem Res toxicol,2020,33(7):1719-1728.

[17] Kloth JS,Pagani A,Verboom MC,et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors[J]. Br J Cancer,2015,112(6):1011-1016.

[18] Pinquié F,de Chabot G,Urban T,et al. Maintenance treatment by erlotinib and toxic cardiomyopathy:a case report[J]. Oncology,2016,90(3):176-177.

[19] Herrmann J. Adverse cardiac effects of cancer therapies:cardiotoxicity andarrythmia[J]. Nat Rev Cardiol,2020,17(8):474-502.

[20] Zhao Q,Cheng J,Chen P,et al. Icotinib:efficacy in different solid tumors and gene mutations[J]. Anticancer Drug,2020,31(3):205-210.

[21] Zeng Z,Yan B,Chen Y,et al. Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma:a retrospective study[J]. Transl Lung Cancer Res,2020,9(6):2401-2410.

[22] Peng LY,Yu M,Yang MX,et al. Icotinib attenuates monocrotaline-induced pulmonary hypertension by preventing pulmonary arterial smooth muscle cell dysfunction[J]. Am J Hypertens,2020,33(8):775-783.

[23] Wecker H,Waller CF. Afatinib[J]. Recent Results Cancer Res,2018,211:199-215.

[24] Nuvola G,Dall’Olio FG,Melotti B,et al. Cardiac toxicity from afatinib in EGFR-mutated NSCLC:a rare but possible side effect[J]. J Thorac Oncol,2019,14(7):e145-e146.

[25] Wu YL,Cheng Y,Zhou X,et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050):a randomised,open-label,phase 3 trial[J]. Lancet Oncol,2017,18(11):1454-1466.

[26] Tan W,Giri N,Quinn S,et al. Evaluation of the potential effect of dacomitinib,an EGFR tyrosine kinase inhibitor,on ECG parameters in patients with advanced non-small cell lung cancer[J]. Invest New Drug,2020,38(3):874-884.

[27] Remon J,Steuer CE,Ramalingam SS,et al. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients[J]. Ann Oncol,2018,29 (Suppl 1):i20-i27.

[28] Anand K. Cardiac dysfunction due to Osimertinib[J]. Lung Cancer,2021,153:193-194.

[29] Shinomiya S,Kaira K,Yamaguchi O,et al. Osimertinib induced cardiomyopathy:a case report[J]. Medicine,2020,99(39):e22301.

[30] Watanabe H,Ichihara E,Kano H,et al. Congestive heart failure during osimertinib treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC) [J]. Intern Med,2017,56(16):2195-2197.

[31] Patel SR,Brown SN,Kubusek JE,et al. Osimertinib-induced cardiomyopathy[J]. JACC Case Rep,2020,2(4):641-645.

[32] Piper-Vallillo AJ,Costa DB,Sabe MA,et al. Heart?failure associated with the epidermal growth factor receptor inhibitor osimertinib[J]. JACC CardioOncol,2020,2(1):119-122.

[33] Ito S,Otsuka A,Ishii H,et al. A case of significant ejection fraction reduction and heart failure induced by osimertinib[J]. Gan To Kagaku Ryoho,2020,47(4):609-613.

[34] Piper-Vallillo AJ,Sequist LV. Cardiac Risk-informed treatment of EGFR-mutant lung cancer with osimertinib[J]. JACC CardioOncol,2019,1(2):179-181.

[35] Lee CS,Sharma S,Miao E,et al. A comprehensive review of contemporary literature for epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer and their toxicity[J]. Lung Cancer(Auckl),2020,11:73-103.

[36] Schiefer M,Hendriks LEL,Dinh T,et al. Current perspective:osimertinib-induced QT prolongation:new drugs with new side-effects need careful patient monitoring[J]. Eur J Cancer,2018,91:92-98.

[37] Oyakawa K,Nakashima K,Naito,T. Cardiac dysfunction caused by osimertinib[J]. J Thorac Oncol,2017,12 (10):e159-e173.

[38] AlAsmari A,Ali N,AlAsmari F,et al. Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioptotection through the regulation of MARK/NF-κB signaling pathways[J]. Saudi Pharm J,2020,28(4)509-518.

相似文献/References:

[1]刘早阳 罗强 汪汉.贝伐单抗治疗非小细胞肺癌的高血压风险：一项系统评价[J].心血管病学进展,2021,(8):753.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.019]
　LIU Zaoyang,LUO Qiang,WANG Han.Hypertension Risk of Bevacizumab for Non-Small-Cell Lung Cancer:A Systematic Review[J].Advances in Cardiovascular Diseases,2021,(2):753.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.019]
[2]王高峰 管丽华 周达新.慢性血栓栓塞性肺动脉高压新治疗方法的进展[J].心血管病学进展,2022,(1):14.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.004]
　WANG Gaofeng,GUAN Lihua,ZHOU Daxin.Chronic Thromboembolic Pulmonary HypertensionEvolving Therapeutic Approaches[J].Advances in Cardiovascular Diseases,2022,(2):14.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.004]
[3]智慧 赵青 柳志红.慢性血栓栓塞性肺动脉高压发病机制新进展：从基础到临床[J].心血管病学进展,2022,(4):297.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.003]
　HUANG Zhihua,LUO Qin,ZHAO Zhihui,et al.Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension:from Bench to Bedside[J].Advances in Cardiovascular Diseases,2022,(2):297.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.003]

更新日期/Last Update: 2022-08-19